Subscribe

Advertisement

Prostate Cancer

Relevant Articles About Prostate Cancer Research and Clinical Trials

RELATED :Bladder Cancer:Renal RCC (Renal Cell Carcinoma)

Stories to Watch

VIEW ALL

VIEW ALL

Advertisement

OncWeekly Featured Trials

Advertisement

Advertisement

LATEST

View More

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy

Latest Conferences

VIEW MORE

Neuro Infection Treatment For Brain
Brain Cancer

Perilesional Edema Predicts SRT Outcome in MBM

KEY TAKEAWAYS The study aimed to investigate the association between SRT efficacy and PEV extent in patients with MBM. Results showed that a larger PEV was associated with a less favorable outcome to SRT in patients with melanoma brain metastases. Stereotactic...

Sep 16, 2024

Latest Conferences

VIEW ALL

VIEW ALL

RELATED CONTENT

VIEW ALL

Enhanced Fuhrman Grading in ccRCC via Radiomics and Spiral CT

KEY TAKEAWAYS

  • The study aimed to investigate the effectiveness of radiomics-based multilayer spiral CT imaging in accurately predicting Fuhrman pathological grading for ccRCC.
  • Researchers noticed that radiomics-based multilayer spiral CT imaging significantly enhances the accuracy of Fuhrman pathological grading in ccRCC.

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC), and accurate pathological grading is essential for prognosis and treatment planning. However, conventional methods using the Fuhrman pathological grading system have significant limitations, often leading to inconsistent and subjective assessments.

Bolin Liu and the team aimed to investigate the potential of using radiomics-based multilayer spiral computed tomography (CT) imaging as a non-invasive, more reliable alternative for predicting Fuhrman pathological grading in ccRCC.

They performed an inclusive retrospective analysis of the clinical data of patients with ccRCC admitted to the hospital from March 2023 to March 2024. The patients were categorized into low-grade (Fuhrman grades I and II) and high-grade (Fuhrman grades III and IV) groups.

Advanced statistical methods, including correlation analysis, receiver operating characteristic (ROC) curves, and the construction of a joint predictive model, were utilized to evaluate the predictive value of radiomics-based multilayer spiral CT imaging indicators for Fuhrman pathological grading in ccRCC. The primary outcome measure focused on determining how effectively these imaging omics indicators could predict the Fuhrman pathological grading in patients with ccRCC.

About 101 patients with ccRCC clinical data were examined, with 56 cases classified as low-grade and 45 cases as high-grade. Notable distinctions were observed in the grey-level co-occurrence matrix (GLCM) features between low and high Fuhrman grading groups, including contrast (0.24 ± 0.08 vs. 0.33 ± 0.09), energy (0.73 ± 0.05 vs. 0.67 ± 0.06), and homogeneity (0.63 ± 0.05 vs. 0.57 ± 0.05) (P < 0.001).

The CT imaging characteristics also demonstrated substantial variation between the low and high Fuhrman grading groups, with enhancement homogeneity (0.34 ± 0.08 vs. 0.26 ± 0.08) and washout half-time (28.57 ± 4.35 vs. 34.72 ± 5.62) showing significant differences (P < 0.001).

Significant correlations were identified between Fuhrman pathological grading and enhancement homogeneity (r = 0.476), washout half-time (r = -0.519), contrast (r = 0.454), energy (r = -0.453), and homogeneity (r = -0.541). The predictive value of these features was highlighted, with a combined imaging genomics model demonstrating an area under the curve of 0.929.

The study concluded that radiomics-based prediction using multilayer spiral CT imaging offers significant potential for accurately predicting Fuhrman pathological grading in clear cell renal cell carcinoma (ccRCC), thereby enhancing the precision of non-invasive diagnostic methods.

No funding information was given.

Source: https://pubmed.ncbi.nlm.nih.gov/39104236/

Liu B, Liu A, Wu Y, et al. (2024). “Enhancing the Efficacy of Radiomics-Based Prediction of Fuhrman Pathological Grading in Renal Clear Cell Carcinoma Using Multilayer Spiral CT Imaging.” Arch Esp Urol. 2024;77(6):674-680. doi:10.56434/j.arch.esp.urol.20247706.92

ERCC Family in Pan-Cancer and ERCC2 in Bladder Cancer

KEY TAKEAWAYS

  • The study aimed to explore ERCC gene expression’s link to prognosis and validate ERCC2’s role in bladder cancer.
  • The ERCC gene family, particularly ERCC2, shows promise as a potential target for cancer treatment due to its association with tumour development and progression.

Single nucleotide polymorphisms (SNPs) within DNA repair genes can disrupt DNA repair mechanisms, potentially causing genetic instability and increasing the risk of cancer, including bladder cancer. The Excision Repair Cross-Complementation (ERCC) family is crucial for nucleotide excision repair, but its impact on bladder cancer prognosis and the immune microenvironment is not yet fully understood.

Siyang Zhang and the team aimed to characterize the ERCC family’s multi-omics profile and investigate its roles in tumour prognosis and the immune microenvironment.

Researchers conducted a bioinformatics analysis using publicly available data from 33 cancer types to examine the association between ERCC gene expression, patient prognosis, and clinical characteristics. The study also included in vitro assays, specifically CCK-8, colony formation, wound healing, and Transwell assays, to validate the role of ERCC2 in bladder cancer.

Analysis revealed a correlation between ERCC expression variations across multiple cancer types, patient prognosis, and the tumour microenvironment (TME). After adjusting for multiple testing using the Benjamini-Hochberg procedure, ERCC expression levels remained significantly correlated with patient prognosis in several cancer types (P< 0.05).

Furthermore, drug sensitivity studies indicated a strong correlation between ERCC expression and the sensitivity of various anticancer drugs. In vitro cell behaviour assays demonstrated that knocking down ERCC2 gene expression significantly inhibited the proliferation, migration, and invasion of bladder cancer cells.

The in-depth analysis of ERCC differential expression and its association with immune-related indicators, the distinctive TME, and patient prognosis has confirmed the potential role of ERCC2 in bladder cancer development and progression. Consequently, the ERCC gene family is anticipated to be a promising candidate for cancer treatment and warrants further exploration.

This work was supported by the Taizhou Science and Technology Program.

Source: https://pubmed.ncbi.nlm.nih.gov/39192988/

Zhang S, Guan Z, Xia Q, et al. (2024). “Bioinformatics analysis of ERCC family in pan-cancer and ERCC2 in bladder cancer.” Front Immunol. 2024;15:1402548. Published 2024 Aug 13. doi:10.3389/fimmu.2024.1402548

APOL6: Biomarker for Immunotherapy Success in Bladder Cancer

KEY TAKEAWAYS

  • The study aimed to assess APOL6 as a biomarker for predicting immunotherapy success in bladder cancer via ferroptosis.
  • Researchers concluded APOL6 may predict immunotherapy success and identified the STAT1/APOL6/GPX4 axis as crucial in BLCA.

Immune checkpoint inhibitors are increasingly used to treat bladder cancer, but effective biomarkers for predicting outcomes remain limited. Ferroptosis, a type of immunogenic cell death, has been shown to improve patient response to these therapies. However, the mechanisms by which ferroptosis enhances immunotherapy effectiveness in bladder cancer are not yet fully understood.

Zhiwei Fan and the team aimed to investigate how ferroptosis influences immunotherapy efficacy in bladder cancer and identify effective biomarkers for predicting treatment outcomes.

Researchers analyzed The Cancer Genome Atlas (TCGA) mRNA data using single sample Gene Set Enrichment Analysis (ssGSEA) to identify 2 distinct immunological subtypes. They used these subtypes, along with other public datasets, to identify Apolipoprotein L6 (APOL6) as a potential biomarker for predicting immunotherapy efficacy. They examined APOL6’s immunological correlations and predictive value, and experimentally validated its role in promoting ferroptosis and regulating this process.

The results showed that APOL6 is highly relevant immunologically and marks immunologically active tumors in bladder cancer and other cancers. APOL6 interacts with acyl-coenzyme A synthetase long-chain family member 4 (ACSL4) to mediate immunotherapy efficacy through ferroptosis. Additionally, APOL6 is regulated by signal transducer and activator of transcription 1 (STAT1).

The study concluded that APOL6 has potential as a predictive biomarker for immunotherapy success and identified the STAT1/APOL6/GPX4 axis as a key regulatory mechanism in bladder cancer.

This work was supported by National Natural Science Foundation of China (82200819), Natural Science Foundation of Jiangsu Province (BK20220605) and Jiangsu Innovative and Enterpreneurial Talent Programme (JSSCBS20211600).

Source: https://pubmed.ncbi.nlm.nih.gov/39187773/

Fan Z, Liu Y, Wang X, et al. (2024) “APOL6 predicts immunotherapy efficacy of bladder cancer by ferroptosis.” BMC Cancer. 2024;24(1):1046. Published 2024 Aug 26. doi:10.1186/s12885-024-12820-7

Low HALP Scores Predict Bladder Cancer Recurrence After UTUC

Low HALP Scores Predict Bladder Cancer Recurrence After UTUC

KEY TAKEAWAYS

  • The study aimed to investigate how the HALP score affects pathologic results and bladder cancer recurrence in patients with UTUC.
  • Results showed that lower HALP scores are linked to advanced disease, higher grade, and increased bladder cancer recurrence risk.

Mehmet Yoldas and the team aimed to investigate how the haemoglobin, albumin, lymphocyte, and platelet (HALP) score impacts pathologic outcomes and bladder cancer recurrence (BCR) in patients who underwent surgery for upper urinary tract tumors (UTUCs).

Researchers calculated HALP scores for all patients. They compared demographic data, preoperative blood parameters, pathologic results, and bladder cancer recurrence status between patients with low and high HALP scores.

Results showed that haemoglobin (11.2±2.3 g/dL vs. 12.9±2.4 g/dL), albumin (4.0±0.8 g/dL vs. 4.4±0.9 g/dL), and HALP score (38.2±2.9 vs. 43.4±3.1) were significantly lower in the BCR (+) group compared with the BCR (-) group (P<0.001). The ROC curve indicated an optimal HALP score cut-off point of 40.8. Multivariate analyses demonstrated that the HALP score was effective for Tumour Grade, Tumour Stage, and BCR.

The study concluded that lower HALP scores are associated with more advanced stages, higher-grade pathologic outcomes, and an increased risk of BCR.

No funding information was available.

Source: https://pubmed.ncbi.nlm.nih.gov/39208822/

Yoldas M, Arikan Y, Kuvvet Yoldas T. (2024). “The Effect of the HALP Score on the Development of Bladder Cancer Recurrence in Patients Undergoing Radical Nephroureterectomy for Upper Urinary Tract Tumours.” Der Einfluss des HALP-Scores auf die Entwicklung eines Blasenkrebsrezidivs bei Patienten, die sich einer radikalen Nephroureterektomie aufgrund eines Tumors des oberen Harntrakts unterziehen. Aktuelle Urol. 2024;55(5):452-457. doi:10.1055/a-2359-7990

Oncological Outcomes of POPRC vs SRC in Female Bladder Cancer

KEY TAKEAWAYS

  • The study aimed to compare oncological outcomes and quality of life between pelvic organ-preserving and SRC in women with bladder cancer.
  • Researchers noticed that stricter criteria and additional evidence are needed for POPRC to ensure optimal oncological outcomes.

Pelvic organ-preserving radical cystectomy (POPRC) has been reported to result in a better postoperative quality of life in females with bladder cancer compared to standard radical cystectomy (SRC). However, its oncological outcomes remain a concern.

Chuanlin Wang and the team aimed to assess the comparative oncological outcomes and quality of life between POPRC and SRC in female bladder cancer patients, addressing the need for more robust evidence to validate the benefits of POPRC in terms of both survival and patient well-being.

They performed an inclusive analysis using data from the Surveillance, Epidemiology, and End Results (SEER) database to identify female bladder cancer patients who underwent either POPRC or SRC. Logistic regression was employed to identify predictors of POPRC usage.

To mitigate the impact of baseline differences on survival outcomes, a 1:2 propensity score matching (PSM) was applied. Kaplan-Meier curves and Log-rank tests were then utilized to assess the significance of overall survival (OS) differences between SRC and POPRC groups. Additionally, subgroup analysis based on predetermined indicators was conducted.

About 2,193 patients were included with a median follow-up of 53 months, of whom 233 (10.6%) received POPRC and 1,960 (89.4%) received SRC. No definitive predictors of POPRC were identified. Before PSM, POPRC resulted in a comparable OS to SRC (HR = 1.09, P = 0.309).

However, after PSM, POPRC was associated with significantly worse OS (HR = 1.23, P = 0.038). In subgroup analyses, POPRC showed non-inferior OS in patients with non-muscle invasive bladder cancer (NMIBC) (HR = 1.18, 95%CI 0.71-1.95, P = 0.531) and T2 patients (HR = 1.07, P = 0.669), but significantly worse OS in T3 patients (HR = 1.41, P = 0.02).

The study concluded that while POPRC currently does not involve strict screening, candidates for POPRC should be subject to more stringent criteria in the future to ensure satisfactory oncological outcomes. However, due to flaws in the study, additional evidence is needed to support these findings.

The study received no funds.

Source: https://pubmed.ncbi.nlm.nih.gov/39182105/

Wang C, Zhang X. (2024). “Pelvic organ-preserving radical cystectomy versus standard radical cystectomy in female patients diagnosed with bladder cancer.” World J Surg Oncol. 2024;22(1):218. Published 2024 Aug 24. doi:10.1186/s12957-024-03502-6

Role of TROAP in RCC Prognosis and Treatment Outcomes

KEY TAKEAWAYS

  • The study aimed to investigate the prognostic significance and therapeutic implications of TROAP across different subtypes of RCC.
  • Researchers found that elevated TROAP levels signify aggressive RCC and therapy resistance.

Trophinin Associated Protein (TROAP) has been implicated in various tumors; however, its role in renal cell carcinoma (RCC) remains largely unexplored.

Qinglin Tan and the team aimed to investigate the prognostic and therapeutic significance of TROAP in RCC, covering multiple subtypes.

Researchers first analyzed TROAP expression across various tumors using data from the TCGA pan-cancer cohort. They then assessed TROAP’s prognostic value in three TCGA RCC cohorts and a local cohort.

To further explore TROAP’s role, they performed functional enrichment analysis, examined somatic mutations and copy number variations, evaluated therapeutic response, and conducted in vitro experiments to investigate TROAP’s biological characteristics.

The results showed that TROAP was a negative factor in TCGA RCC datasets and the local cohort. Functional enrichment and in vitro experiments showed that TROAP acts as an oncogene, promoting tumor growth. The link between TROAP expression and gene mutations in RCC seems minimal. Moreover, high TROAP levels are linked to lower effectiveness of RCC treatments, including nivolumab and everolimus.

The study concluded that TROAP is a crucial RCC biomarker for prognosis and therapy response. High TROAP expression indicates aggressive tumor behavior and resistance to conventional treatments, highlighting its potential as a target for personalized RCC therapies.

The study was funded by the Guangdong Basic and Applied Basic Research Foundation.

Source: https://pubmed.ncbi.nlm.nih.gov/39153983/

Tan Q, Kong P, Chen G, et al. (2024). “Evaluating trophinin associated protein as a biomarker of prognosis and therapy response in renal cell carcinoma.” BMC cancer, 24(1), 1021. https://doi.org/10.1186/s12885-024-12802-9

Effect of Race, Stage, and Surgery on SRCC Treatment

KEY TAKEAWAYS

  • The study aimed to identify key factors influencing prognosis and evaluate how treatments impact survival outcomes.
  • Results showed race, TNM stage, and surgical approach predict SRCC outcomes; simple and partial cystectomy are effective.

Signet ring cell carcinoma (SRCC) of the urinary bladder is a rare, aggressive cancer with no standard treatment strategy.

Yingwei Xie and the team aimed to identify key factors affecting prognosis and evaluate the impact of different treatments on survival outcomes.

The study used data from the Surveillance, Epidemiology, and End Results (SEER) Program, focusing on patients with bladder primary SRCC from 2000 to 2017. Researchers applied univariate and multivariate Cox regression models to assess how various factors affected cancer-specific survival (CSS) and overall survival (OS).

To ensure comparable groups, they used propensity score matching (PSM) and inverse probability of treatment weighting (IPTW). The Kaplan-Meier method analyzed the effects of different treatment regimens on CSS and OS.

The study included 33 cases of non-muscle invasive SRCC and 210 cases of muscle invasive SRCC. Multivariate analysis identified race, TNM stage, and surgical method as independent factors affecting both OS and CSS.

In patients with non-muscle invasive bladder SRCC, radical cystectomy did not show a CSS benefit compared to transurethral resection of bladder tumors (P= 0.304). For muscle invasive SRCC, patients who had partial cystectomy experienced better OS and CSS than those who had radical cystectomy (P= 0.019, P= 0.024).

However, post-propensity score matching (PSM) analysis showed no significant differences between the 2 surgical outcomes (P= 0.504, P= 0.335). Lymphadenectomy, chemotherapy, and radiation did not improve patient prognosis.

The study found that race, TNM stage, and surgical approach are significant independent predictors of SRCC outcomes. Simple radical cystectomy and partial cystectomy were effective treatments for SRCC. The best treatment option still requires further validation through prospective research trials.

This work was supported by the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (XMLX202134), the National Natural Science Foundation of China (No. 82072833, 82272864).

Source: https://pubmed.ncbi.nlm.nih.gov/39159955/

Xie Y, Zhang Y, Du Z, et al. (2024). “Treatment Options for Signet Ring Cell Carcinoma of the Urinary Bladder: A Population-Based Study.” Cancer Control. 2024;31:10732748241278485. doi:10.1177/10732748241278485

VIEW ALL

SELECT ONCOLOGY JOURNAL ARTICLES

Meta-analysis of Targeted Therapies in EGFR-mutated Non–Small Cell Lung Cancer: Efficacy and Safety of Osimertinib, Erlotinib, and Gefitinib as First-line Treatment

Meta-analysis of Targeted Therapies in EGFR-mutated Non–Small Cell Lung Cancer: Efficacy and Safety of Osimertinib, Erlotinib, and Gefitinib as First-line Treatment

Background: Some of the non–small cell lung cancer (NSCLC) cases enhance somatic mutations of the epidermal growth factor receptor (EGFR) gene within the tyrosine kinase inhibitor (TKI) domain. In such cases, first-line treatments are EGFR-TKIs, …

American Journal of Clinical Oncology

Assessing the Impact of Multidisciplinary Cancer Consultations on Cancer Quality Metrics

Assessing the Impact of Multidisciplinary Cancer Consultations on Cancer Quality Metrics

Objective: Multidisciplinary cancer consultations play a critical role in the delivery of quality cancer care by promoting treatment planning and collaborative decision-making. The objective of this study was to evaluate associations between multidisciplinary cancer consultations …

American Journal of Clinical Oncology

Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2− Advanced or Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2− Advanced or Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

Objectives: Breast cancer, particularly the hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) subtype, remains a major global health concern. Abemaciclib, a CDK4/6 inhibitor, has shown promising results in treating advanced cases. …

American Journal of Clinical Oncology

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >=1%: results from a multicenter, open-label, phase 2 trial

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >=1%: results from a multicenter, open-label, phase 2 trial

Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase …

BMJ Journals